Predicting the outcome of ankylosing spondylitis therapy

Predicting the outcome of ankylosing spondylitis therapy

Objectives To create a model that provides a potential basis for candidate selection for anti-tumour necrosis factor (TNF) treatment by predicting future outcomes relative to the current disease profile of individual patients with ankylosing spondylitis (AS). Methods ASSERT and GO–RAISE trial data (...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awduron:	Nathan Vastesaeger, Désirée van der Heijde, Robert D. Inman, Yanxin Wang, Atul Deodhar, Benjamin Hsu, Mahboob U. Rahman, Ben A. C. Dijkmans, Piet Geusens, Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Joachim Sieper, Jürgen Braun
Fformat:	Artigo
Iaith:	Saesneg
Cyhoeddwyd:	2011
Mynediad Ar-lein:	https://doi.org/10.1136/ard.2010.147744 https://ard.bmj.com/content/annrheumdis/70/6/973.full.pdf
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Predicting the outcome of ankylosing spondylitis therapy
gan: Vastesaeger, Nathan, et al.
Cyhoeddwyd: (2011)

Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
gan: Bert Vander Cruyssen, et al.
Cyhoeddwyd: (2009)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
gan: van der Heijde, Désirée, et al.
Cyhoeddwyd: (2019)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
gan: Désirée van der Heijde, et al.
Cyhoeddwyd: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
gan: Braun, Jürgen, et al.
Cyhoeddwyd: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
gan: Wagner, Carrie, et al.
Cyhoeddwyd: (2011)

Ankylosing spondylitis: an overview
gan: Joachim Sieper, et al.
Cyhoeddwyd: (2002)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
gan: Deodhar, Atul, et al.
Cyhoeddwyd: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
gan: Atul Deodhar, et al.
Cyhoeddwyd: (2014)

Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
gan: Braun, J, et al.
Cyhoeddwyd: (2002)

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
gan: Désirée van der Heijde, et al.
Cyhoeddwyd: (2014)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
gan: Dominique Baeten, et al.
Cyhoeddwyd: (2015)

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2005)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2011)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2023)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
gan: Inman, Robert D., et al.
Cyhoeddwyd: (2016)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
gan: Xenofon Baraliakos, et al.
Cyhoeddwyd: (2023)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
gan: Braun, Jürgen, et al.
Cyhoeddwyd: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2013)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice
gan: Cruyssen, Bert Vander, et al.
Cyhoeddwyd: (2007)

The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
gan: Bert Vander Cruyssen, et al.
Cyhoeddwyd: (2007)

Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
gan: Annelies Boonen, et al.
Cyhoeddwyd: (2009)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
gan: Braun, Jürgen, et al.
Cyhoeddwyd: (2018)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
gan: Sambrook, Philip N., et al.
Cyhoeddwyd: (2012)

The epidemiology of osteoporosis and fractures in ankylosing spondylitis
gan: Philip N. Sambrook, et al.
Cyhoeddwyd: (2012)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
gan: Braun, Jürgen, et al.
Cyhoeddwyd: (2011)

ASAS/EULAR recommendations for the management of ankylosing spondylitis
gan: Zochling, J, et al.
Cyhoeddwyd: (2006)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
gan: Désirée van der Heijde, et al.
Cyhoeddwyd: (2022)

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis
gan: Ben A. C. Dijkmans, et al.
Cyhoeddwyd: (2009)

Ankylosing spondylitis: an overview
gan: Sieper, J, et al.
Cyhoeddwyd: (2002)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
gan: Sudha Visvanathan, et al.
Cyhoeddwyd: (2008)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
gan: Braun, J, et al.
Cyhoeddwyd: (2011)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2002)

Definition of disease duration in ankylosing spondylitis: reassessing the concept
gan: Davis, J C, et al.
Cyhoeddwyd: (2006)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
gan: Désirée van der Heijde, et al.
Cyhoeddwyd: (2007)

Staging of patients with ankylosing spondylitis: a preliminary proposal
gan: Braun, J, et al.
Cyhoeddwyd: (2002)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
gan: Désirée van der Heijde, et al.
Cyhoeddwyd: (2008)

Determinants of hyperkyphosis in patients with ankylosing spondylitis
gan: Vosse, D, et al.
Cyhoeddwyd: (2006)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
gan: Jürgen Braun, et al.
Cyhoeddwyd: (2016)